HealthScience Centers

Transformative Medicine…Transformative Healthcare

Founded by Nathan Sassover, the healthcare model envisioned for the HealthMedica HealthScience Centers currently being established, is to unify evidence-based integrative health enhancement conjoining longevity science, pharmacogenomics and personalized medicine, within a physician administered clinical setting.

HealthMedica clinical programs evolved as a response to the increasing challenges in care giving which attend the daily practice of medicine in the clinical arenas of age-related degenerative disorders and multi-category cancer therapeutics.

HealthMedica HealthScience centers address two of the central components of the healthcare challenges in the US, and are committed to a transformative model advancing both preventive and interventional therapeutics. HealthMedica’s focus is on advancing safe and effective new treatment programs which have demonstrated clinically validated therapeutic platforms.

IECT: IntraTherapies Epigenetic Cancer Therapeutics: an Oncology Treatment Program based on molecular cancer genetics and DNA programmable genetic pharmacology to inhibit the growth replication and proliferation of human cancer cells.

During the past three years, Mr. Sassover’s IntraTherapies Institute has further pursued cancer research, specifically, molecular cancer genetics. Utilizing DNA programmable Genetic Pharmacology to inhibit the growth and replication of human cancer cells, IECT’s hybrid clinical protocols and pathway-specific compounds are administered within the FDA compliant and recognized ‘off label’ mode as a monotherapy, or administered in conjunction with metronomic low dose chemotherapy. The primary mode of disease intervention consists of re-programming of genetic information adjacent to the primary DNA code. This enables gene silencing and gene reactivation within the alterable regions of the DNA which is independent of the DNA sequence. These programmable aspects of the human genome are pharmaceutically controllable and programmable for elimination of abnormal cell structures which may evolve over time to become various types of cancer. This integrative pathway-specific approach defines IntraTherapies Epigenetic Cancer Therapeutics.

IntraTherapies clinically validated results, based on radiology oncology reports, hematology laboratory data were obtained during an 8 week investigational study in Stage IIIB and Stage IV breast and colon cancer patients utilizing the IECT oncology treatment the next phase of IntraTherapies oncology programs will be initiated across a broader patient population and extending to six cancer categories as follows:

- Advanced (Stage III and IV) Breast Cancer
- Metastatic (Stage IV) Colon Cancer
- Metastatic (Stage IV) Castration-Resistant Prostate Cancer (CRPC)
- Advanced (Stage III and IV) Non Small Cell Lung Cancer (NSCLC)
- Advanced (Stage III and IV) Ovarian Cancer
- Metastatic (Stage IV) Renal Cell Carcinoma (Kidney Cancer)

IntraTherapies utilizes targeted combination therapies and pathway-specific drug compounds to achieve broader cancer interventional effect with enhanced safety at the cellular level, absent adverse impact on major cellular pathways, thereby resulting in reduction of treatment toxicity levels across six primary cancer categories. Although within a small patient group, this conjunctive treatment approach has clinically demonstrated, during an eight week clinical investigational study, the ability to inhibit the growth, replication and proliferation of human cancer cells.

IECT: IntraTherapies Epigenetic Cancer Therapeutics: an Oncology Treatment Program based on molecular cancer genetics and DNA programmable genetic pharmacology to inhibit the growth replication and proliferation of human cancer cells.

These statements are based on published medical research data from the National Cancer Institute and other independent accredited medical institutions in peer-reviewed oncology/hematology publications worldwide. The increasing degree of medical/scientific empirical evidence supporting the pharmaceutical ingredients which comprise IntraTherapies Epigenetic Cancer Therapeutics (IECT) is based on independent research originating in numerous recognized medical/biological research centers in the US and Overseas, namely,

- Indiana University School of Medicine; Indiana University Cancer Center - Departments of Surgery and Biochemistry/Molecular Biology and Walther Oncology Center; Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Centre; Osaka University Graduate School of Medicine - Japan.

Added to this scientific consensus, increasing clinical evidence and empirical data, published research about the specific chemical agents which are the primary active ingredients in all IntraTherapies Epigenetic Cancer Therapeutics compounds have appeared over the past several years in peer-reviewed and recognized clinical oncology journals such as:

- Cancer Research / American Association for Cancer Research; Current Opinion in Oncology, Journal of Pharmacological Sciences, Elsevier Cancer Letters, Molecular Cancer Therapeutics, Modern Pathology; as well as JNCI - Journal of the National Cancer Institute.

These publications reaffirm and recognize the epigenetic compounds comprising IntraTherapies epigenetic cancer protocols as clinically and verifiably significant in controlling gene expression and cancer cell replication in oncology-based diseases.

Epigenetics refers to the function of DNA that does not depend on the coding DNA sequence itself but on the accessory molecules and mechanisms affected by DNA. It is known that epigenetic alterations are equally if not more important than classical genetic alterations to disrupt the function of tumor suppressor genes.

Scientists are increasingly recognizing that to understand human health and disease - not just what causes disease but how to prevent and reverse it - they need to know more than what kind of genes someone has, or what the DNA sequence of their genome is. Equally, if not more important, they need to know how cells use that genomic information. That is what epigenetics is all about: how genomic information encoded in the DNA sequence is regulated by other, non DNA-sequence factors each of which plays a key role in gene expression by allowing or preventing transcription to proceed - that is, by turning genes on and off.

These statements have not been evaluated by the FDA. These programs and products are not intended to diagnose, treat, cure or prevent any diseases.